Front Runners: E2open, Inc. (EOPN), Covenant Transportation Group (CVTI), Vitae Pharmaceuticals (VTAE), Veeva Systems (VEEV), GoPro (GPRO)

E2open, Inc. (EOPN) shares are up 16% to $7.20 in mid-day trading. The move comes on a big volume too with the issue currently trading more than 949K shares, compared to the average volume of 382K. Not seeing any news or rumors to account for the move.

E2open is a cloud-based, on-demand software solutions provider. Its stock has a median consensus analyst price target of $11.00 with a high target of $13.00, and a 52-week trading range of $5.31 to $29.82.

The T-12 profit margin at E2open, Inc. is (39.69%). EOPN‘s revenue for the same period is $76.64 million.

E2open has market cap of $210.30 million.

Covenant Transportation Group, Inc. (CVTI) hit a new 52-week high Wednesday, surpassing their previous high of $25.08 set on November 24, 2014. That’s an 8.09% rise, or $20 per share, from the 52-week low of $7.21.

The stock closed at $25.77 at the end of Tuesday’s trading session, printing a staggering one-year return of about 233.7% and year-to-date return of around 230%, outperforming the S&P 500 by 215.62%. The average volume of shares traded over the last three months was roughly 207K.

This Chattanooga, Tennessee-based company offering truckload transportation and brokerage services in the continental United States, has a current market cap of $406.60 million and long-term expected earnings growth of 5%. The trailing-twelve-month revenue at Covenant Transportation Group is $688.68 million. CVTI’s EPS for the same period is $0.50.

In today’s session, the equity is 5.17%% higher, changing hands at $27.10 a share.

Shares of Vitae Pharmaceuticals, Inc. (VTAE) hit a new 52-week high Wednesday, printing the tape at $19.63. That’s a 262.84% rise from the 52-week low of $5.41 set on Oct 15, 2014.

Vitae Pharmaceuticals, currently valued at $336.31M, has a median Wall Street price target of $21.00 with a high target of $22.00. Approximately 219K shares have already changed hands compared to the stock’s average daily volume of 316.24K.

In the past 52 weeks, shares of Fort Washington, Pennsylvania-based firm have traded between a low of $5.41 and a high of $19.63 with the 50-day MA and 200-day MA located at $12.15 and $11.20 levels, respectively. Additionally, shares of VTAE have a Relative Strength Index (RSI) and MACD indicator of 73.45 and +0.79, respectively.

Vitae Pharmaceuticals currently prints a year-to-date return of around 129.04%.

Shares of Veeva Systems Inc. (VEEV) climbed over 9% Wednesday to $31.55, boosted by JPMorgan (JPM) analysts who raised their VEEV price target to $36 from $35 with an ‘Overweight’ rating. In a note to investors, the broker said the company is getting stronger and expects the stock to outperform the market for quite some time.

In other Veeva news this morning, the company reported third quarter (October) earnings of $0.09 per share, $0.01 better than the Capital IQ consensus estimate of $0.08. Revs were $83.8 million, up from $55.0 million one year ago, an increase of 52% year-over-year.

Guidance: The company issued upside guidance for Q4, saying it sees EPS of $0.08-$0.09 versus Capital IQ consensus estimate $0.07 consensus estimate ; sees Q4 total revs between $84.5 and $85.5 million versus $81.62 million consensus estimate.

Veeva Systems a cloud-based software solutions provider for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America. The company was founded in 2007 and is headquartered in Pleasanton, California.

GoPro, Inc. (GPRO) shares are ripping to session highs following a WSJ report that said the company is developing its own line of consumer drones to expand from its core business of making wearable video cameras. The San Mateo, Calif.-based firm plans to start selling multi-rotor helicopters with high-def cameras late next year for between $500 to $1,000 each, the sources told the newspaper.

GoPro shares recently traded at $77.43, up 3.63%.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.